EUCTR2009-015198-11-ES进行中（未招募）不适用
A Phase 3, Randomized, Placebo and Active Control, Observer Blind Trial to Assess the Safety, Tolerability and Immunogenicity of a Meningococcal Serogroup B Recombinant Lipoprotein (rLP2086) Vaccine Given in Healthy Subjects Aged >=11 to <26 Years
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 7,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator?s study team before subjects are included in the study. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1.Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •2.Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3.Male or female subjects aged ?11 and <26 years at time of enrollment.
- •4.Available for the entire study period and can be reached by telephone.
- •5.Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
- •6.Parent/legal guardian and/or subject must be able and willing to complete all relevant study procedures during study participation.
- •7.All male and female subjects must agree to practice a form of effective contraception, such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm, cervical cap or intrauterine device), implants, injectables, combined oral contraceptives or sexual abstinence prior to entering into the study, for the duration of the vaccination period and for 28 days after the last study vaccination. For Germany: The phrase ?sexual abstinence? is not applicable, with the understanding that all male and female subjects of childbearing potential must practice an effective form of contraception during the study.
- •8.Negative urine pregnancy test for female subjects.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 4103
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3397
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •1.Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.
- •2.Subject is a direct descendant (e.g. child, grandchild or other family member) of study site personnel.
- •3.Previous vaccination with any meningococcal serogroup B vaccine.
- •4.Subjects who have received prior HAV vaccination.
- •5.Contraindication to vaccination with any HAV vaccine.
- •6.A previous anaphylactic reaction to any vaccine or vaccine related component.
- •7.Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
- •8.A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function or those receiving immunosuppressive therapy. Subjects with terminal complement deficiency may be included. Please refer to the SRM additional details.
- •9.History of culture proven disease caused by Neisseria meningitidis or Neisseria gonorrhoea.
- •10.Significant neurological disorder or history of seizure (excluding simple febrile seizure).
- •11.Receipt of any blood products, including immunoglobulin within 6 months before the first study vaccination.
- •12.Current participation in another investigational study. Participation in purely observational studies is acceptable.
- •13.Received any investigational drugs or devices within 28 days before administration of the first study vaccination.
- •14.Any neuroinflammatory and autoimmune condition, including but not limited to transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
- •15.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •16.Subject is pregnant or breastfeeding.
研究者
相似试验
进行中（未招募）
不适用
Phase 3, Adolescent Large Scale Safety StudyBacterial MeningitisMedDRA version: 14.0Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-015198-11-DKPfizer Inc, 235 East 42nd Street, New York, NY 100177,500
未知
3 期
MK-0431A/ONO-5435A Phase III Clinical Trial -Metformin Add-on Regimen Comparison Study in Japanese Patients with Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080221725MSD K.K. and ONO PHARMACEUTICAL CO.,LTD.337
进行中（未招募）
不适用
A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial toStudy the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely PsychoticPatients with SchizophreniaSchizophreniaEUCTR2007-003820-40-LTDainippon Sumitomo Pharma America, Inc.490
已完成
不适用
urasidone HCl A Phase 3 Study of Patients With Acute SchizophreniaPER-052-08DAINIPPON SUMITOMO PHARMA AMERICA, INC,
招募中
3 期
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyHidradenitis SuppurativaJPRN-jRCT2061230029Yamazaki Hayato1,328